Streetbeat News

TARS

Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com

Industry

Biotechnology

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Open

49.30

Mkt cap

1.9B

Volume

422K

High

50.20

P/E Ratio

-13.01

52-wk high

57.14

Low

48.08

Div yield

N/A

52-wk low

20.08

Tarsus Pharmaceuticals (TARS) has experienced a 9.11% decline over the past four weeks, but it may be poised for a turnaround. The stock is in oversold territory, and Wall Street analysts are revising earnings estimates higher, suggesting a potential trend reversal.

Portfolio Pulse from

January 14, 2025 | 4:00 pm

Tarsus Pharmaceuticals is accelerating the launch of XDEMVY® and advancing TP-04 for ocular rosacea treatment, with a Phase 2 study planned for the second half of 2025.

Portfolio Pulse from

January 13, 2025 | 1:45 pm

Wall Street analysts suggest a potential 27% upside for Tarsus Pharmaceuticals (TARS) based on consensus price targets. Despite skepticism about the effectiveness of price targets, positive earnings estimate revisions could indicate a near-term stock price increase.

Portfolio Pulse from

December 04, 2024 | 4:15 pm

Wall Street analysts have set an average price target for Tarsus Pharmaceuticals (TARS) that suggests a potential upside of 41.1%. This optimism is supported by positive trends in earnings estimate revisions, which could lead to a stock price increase.

Portfolio Pulse from

November 18, 2024 | 4:15 pm

Tarsus Pharmaceuticals, Inc. held its Q3 2024 earnings call, discussing financial results and company updates. Key participants included executives and analysts from major financial institutions.

Portfolio Pulse from

November 14, 2024 | 3:45 am

Tarsus Pharmaceuticals, Inc. (TARS) reported a Q3 loss of $0.61 per share, which is better than the Zacks Consensus Estimate of a $0.90 loss. This is an improvement from the $1.28 loss per share reported a year ago.

Portfolio Pulse from

November 13, 2024 | 11:45 pm

Tarsus Pharmaceuticals has appointed Dr. Kate Goodrich, the Chief Medical Officer of Humana, to its Board of Directors. Dr. Goodrich brings over 20 years of experience in value-based healthcare initiatives aimed at enhancing patient outcomes.

Portfolio Pulse from

November 13, 2024 | 1:45 pm

Tarsus Pharmaceuticals (TARS) is expected to surpass earnings estimates in its upcoming report, driven by favorable conditions. Investors are optimistic about the potential positive impact on the stock price.

Portfolio Pulse from

November 07, 2024 | 4:15 pm

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will report its Q3 2024 financial results on November 13, 2024, via a live webcast. The company focuses on unmet medical needs, particularly in eye care.

Portfolio Pulse from

November 06, 2024 | 9:45 pm

Tarsus Pharmaceuticals shares surged as rumors circulated about two major pharmaceutical companies potentially competing to acquire the company.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 5:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.